BACKGROUND: Monitoring of platelet activation by the ADVIA 120 Hematology System requires an anticoagulant and protocol that ensures that platelets are sphered and their activation status is not altered artifactually in vitro. METHODS: Blood from healthy controls was collected into tripotassium EDTA; citrate, theophylline, adenosine, and dipyridamole (CTAD); or a combination of both (E/C) and stored at ambient temperature or at 4 degrees C (E/C only) and then analyzed between 0 and 180 min later on the ADVIA 120. In addition, immunofluorescent flow cytometry was used to identify activated platelets and platelet-leukocyte aggregates. RESULTS: In blood stored with all three anticoagulants, the platelet count changed little, but the mean platelet volume (MPV) at first decreased and then increased, whereas the mean platelet component (MPC; an indicator of activation) changed in a reciprocal manner. The changes in MPV and MPC, which reflect platelet sphering and swelling, were greatest between 30 and 60 min in blood stored at ambient temperature, irrespective of which anticoagulant was used, and between 60 and 180 min when blood anticoagulated with E/C was stored at 4 degrees C. In all anticoagulants, the percentages of platelets expressing CD62P and of leukocytes in platelet-leukocyte aggregates increased significantly (P <0.01) over 180 min at ambient temperature. Only minimal (<2%) increases occurred when blood with E/C was stored at 4 degrees C. CONCLUSIONS: When determining platelet activation ex vivo on the ADVIA 120, blood should be collected into E/C, stored at 4 degrees C, and analyzed between 60 and 180 min later; these conditions ensure maximum platelet sphering without concurrent artifactual platelet activation.
BACKGROUND: Monitoring of platelet activation by the ADVIA 120 Hematology System requires an anticoagulant and protocol that ensures that platelets are sphered and their activation status is not altered artifactually in vitro. METHODS: Blood from healthy controls was collected into tripotassium EDTA; citrate, theophylline, adenosine, and dipyridamole (CTAD); or a combination of both (E/C) and stored at ambient temperature or at 4 degrees C (E/C only) and then analyzed between 0 and 180 min later on the ADVIA 120. In addition, immunofluorescent flow cytometry was used to identify activated platelets and platelet-leukocyte aggregates. RESULTS: In blood stored with all three anticoagulants, the platelet count changed little, but the mean platelet volume (MPV) at first decreased and then increased, whereas the mean platelet component (MPC; an indicator of activation) changed in a reciprocal manner. The changes in MPV and MPC, which reflect platelet sphering and swelling, were greatest between 30 and 60 min in blood stored at ambient temperature, irrespective of which anticoagulant was used, and between 60 and 180 min when blood anticoagulated with E/C was stored at 4 degrees C. In all anticoagulants, the percentages of platelets expressing CD62P and of leukocytes in platelet-leukocyte aggregates increased significantly (P <0.01) over 180 min at ambient temperature. Only minimal (<2%) increases occurred when blood with E/C was stored at 4 degrees C. CONCLUSIONS: When determining platelet activation ex vivo on the ADVIA 120, blood should be collected into E/C, stored at 4 degrees C, and analyzed between 60 and 180 min later; these conditions ensure maximum platelet sphering without concurrent artifactual platelet activation.
Authors: Rachael Simon-Walker; John Cavicchia; David A Prawel; Lakshmi Prasad Dasi; Susan P James; Ketul C Popat Journal: J Biomed Mater Res B Appl Biomater Date: 2017-09-30 Impact factor: 3.368
Authors: Lalitha Muthusubramaniam; Rachel Lowe; William H Fissell; Lingyan Li; Roger E Marchant; Tejal A Desai; Shuvo Roy Journal: Ann Biomed Eng Date: 2011-02-02 Impact factor: 3.934
Authors: Adriana Aguilar-Mahecha; Michael A Kuzyk; Dominik Domanski; Christoph H Borchers; Mark Basik Journal: PLoS One Date: 2012-06-06 Impact factor: 3.240
Authors: Peter Schuff-Werner; Michael Steiner; Sebastian Fenger; Hans-Jürgen Gross; Alexa Bierlich; Katrin Dreissiger; Steffen Mannuß; Gabriele Siegert; Maximilian Bachem; Peter Kohlschein Journal: Br J Haematol Date: 2013-06-29 Impact factor: 6.998
Authors: Kenneth W Witwer; Edit I Buzás; Lynne T Bemis; Adriana Bora; Cecilia Lässer; Jan Lötvall; Esther N Nolte-'t Hoen; Melissa G Piper; Sarada Sivaraman; Johan Skog; Clotilde Théry; Marca H Wauben; Fred Hochberg Journal: J Extracell Vesicles Date: 2013-05-27
Authors: Peter J O'Brien; Rajeev Ramanathan; Jonathan M Yingling; Jose Baselga; Mace L Rothenberg; Michael Carducci; Thomas Daly; Dorothy Adcock; Michael Lahn Journal: Biologics Date: 2008-09